Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Central Nervous System Neoplasms × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Temozolomide 13 Radiotherapy 13 Carboplatin 7 Irinotecan 6 Everolimus 5 Filgrastim 4 Carmustine 4 Surgical Procedures, Operative 3 Radiation 3 Paclitaxel 3 Ifosfamide 3 selpercatinib 2 pembrolizumab 2 Trastuzumab 2 Peripheral Blood Stem Cell Transplantation 2 Methotrexate 2 Imatinib Mesylate 2 IL13-PE38 2 Dasatinib 2 Bevacizumab 2 vitespin 1 veliparib 1 vatalanib 1 transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1 tipifarnib 1 terameprocol 1 temsirolimus 1 talazoparib 1 sodium thiosulfate 1 regorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05222165 2023-02-23

NEWEL

Helsinn Healthcare SA

Phase 1/2 Withdrawn

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡